Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
01 08 2020
Historique:
received: 31 03 2020
revised: 13 04 2020
accepted: 20 04 2020
pubmed: 20 5 2020
medline: 23 7 2020
entrez: 20 5 2020
Statut: ppublish

Résumé

Coronavirus disease 2019 (COVID-19) has become a global pandemic. It is still uncontrolled in most countries and no therapies are currently available. Various drugs are under investigation for its treatment. The disease is known to have worse outcomes in patients who have underlying cardiovascular disease. Chloroquine/hydroxychloroquine, azithromycin, remdesivir and lopinavir/ritonavir are currently being studied in trials and show some promise. Conduction disorders, heart failure, and mortality have been reported with the use of these drugs. It is important to have knowledge of potential cardiotoxic effects of these drugs before using them for COVID-19 patients for better allocation of healthcare resources and improvement in clinical outcomes.

Identifiants

pubmed: 32425199
doi: 10.1016/j.amjcard.2020.04.054
pii: S0002-9149(20)30489-6
pmc: PMC7228893
pii:
doi:

Substances chimiques

Anti-Infective Agents 0
Drug Combinations 0
Enzyme Inhibitors 0
lopinavir-ritonavir drug combination 0
Lopinavir 2494G1JF75
remdesivir 3QKI37EEHE
Adenosine Monophosphate 415SHH325A
Hydroxychloroquine 4QWG6N8QKH
Azithromycin 83905-01-5
Ritonavir O3J8G9O825
Alanine OF5P57N2ZX

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

147-150

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosures The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Mil Med Res. 2020 Mar 13;7(1):11
pubmed: 32169119
Int J Cardiol. 1983 Sep;4(2):198-200
pubmed: 6629533
Pak J Med Sci. 2020 May;36(COVID19-S4):S73-S78
pubmed: 32582318
Circulation. 2006 Aug 22;114(8):e357-8
pubmed: 16923761
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Ann Fam Med. 2014 Mar-Apr;12(2):121-7
pubmed: 24615307
N Engl J Med. 2013 May 2;368(18):1704-12
pubmed: 23635050
Am J Clin Nutr. 2004 Nov;80(5):1194-200
pubmed: 15531665
J Am Coll Cardiol. 2015 Nov 17;66(20):2173-2184
pubmed: 26564594
PLoS Negl Trop Dis. 2017 Dec 28;11(12):e0006034
pubmed: 29283993
CMAJ. 2017 Apr 18;189(15):E560-E568
pubmed: 28420680
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
Rheumatology (Oxford). 2007 May;46(5):808-10
pubmed: 17202178
J Am Heart Assoc. 2017 Mar 13;6(3):
pubmed: 28288972
N Engl J Med. 2012 May 17;366(20):1881-90
pubmed: 22591294
Drug Saf. 2018 Oct;41(10):919-931
pubmed: 29858838
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Jpn Heart J. 1996 Nov;37(6):905-15
pubmed: 9057685
Med Lett Drugs Ther. 2013 Apr 1;55(1413):28
pubmed: 23545583
CMAJ. 2016 Apr 19;188(7):E120-E129
pubmed: 26903359
Sex Health. 2009 Sep;6(3):254-7
pubmed: 19653965
Korean Circ J. 2010 Nov;40(11):604-8
pubmed: 21217940
N Engl J Med. 2019 Dec 12;381(24):2293-2303
pubmed: 31774950
PLoS One. 2016 Aug 31;11(8):e0160306
pubmed: 27579612
Circ Arrhythm Electrophysiol. 2017 Apr;10(4):
pubmed: 28408648
Int J Cardiol. 2008 Jul 4;127(2):e80-2
pubmed: 17590456
Curr Probl Cardiol. 2020 Aug;45(8):100617
pubmed: 32402515
Immunol Lett. 2013 Jun;153(1-2):50-7
pubmed: 23891850

Auteurs

Gaurav Aggarwal (G)

Jersey City Medical Center, Jersey City, New Jersey.

Brandon Michael Henry (BM)

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.

Saurabh Aggarwal (S)

Unitypoint Clinic, Des Moines, Iowa.

Sripal Bangalore (S)

New York University School of Medicine, New York City New York. Electronic address: sripalbangalore@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH